Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00099112
Other study ID # CDR0000357437
Secondary ID NCI-04-C-0120
Status Completed
Phase N/A
First received December 8, 2004
Last updated April 29, 2015
Start date February 2004

Study information

Verified date November 2005
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

RATIONALE: Testing of skin that has been exposed to artificial sunlight may help in understanding the genetic processes involved in the development of skin cancer.

PURPOSE: This trial is studying the effect of solar-simulated ultraviolet radiation on skin with or without sunscreen in healthy adults with skin that burns easily after only slight tanning during sun exposure.


Description:

OBJECTIVES:

- Determine the global gene expression profiles in epidermal tissue of healthy fair-skinned adults with Fitzpatrick skin type II after exposure to known doses of solar-simulated ultraviolet radiation (ssUVR) (UVA).

- Determine the ability of an FDA-standardized sunscreen to alter ssUVR-induced transcription profiles in vivo in these participants.

- Determine whether the transcriptional profiles of keratinocytes exposed to UVR in cell culture are comparable to the profiles of keratinocytes in skin after similar levels of UVR exposure.

OUTLINE: This is a pilot, dose-response study followed by an in vivo transcriptional profiling study in 2 different groups.

- Pilot study (verification of ultraviolet radiation dose response): Participants are initially exposed to solar-simulated ultraviolet radiation (ssUVR) (UVA) on the back to determine the minimum erythema dose (MED). Between 22-24 hours after exposure, participants undergo shave biopsy from each of the 9 UV exposure sites and 1 unexposed skin site.

- Group 1 (determination of ssUVR and UVA in vivo transcriptional profiles): On day 1, participants are initially exposed to ssUVR on the back to determine the MED. On day 2, participants are exposed to ssUVR (3 sites) and UVA (3 sites) at the MED on the buttocks. Between 22-24 hours after exposure (day 3), participants undergo shave biopsy from each of the 6 UV exposure sites and 2 unexposed skin sites.

- Group 2 (determination of sunscreen-protected in vivo transcriptional profiles): On day 1, participants are initially exposed to ssUVR on the back to determine the MED. On day 2, participants are exposed to ssUVR on unprotected skin (3 sites) and sunscreen-protected skin (3 sites) at the MED on the buttocks. Between 22-24 hours after exposure (day 3), participants undergo shave biopsy from each of the 6 UV exposure sites and 2 unexposed skin sites.

Biopsies from all participants are analyzed by microarray analysis. One of the unexposed epidermal samples is used for primary keratinocyte culture.

PROJECTED ACCRUAL: A total of 6-56 participants (6 for the pilot study and 50 [25 per group] for transcriptional profiling) will be accrued for this study within 2 months.


Other known NCT identifiers
  • NCT00077740

Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility DISEASE CHARACTERISTICS:

- Healthy, fair-skinned adults

- Fitzpatrick skin type II by history and physical exam

- Skin easily burns, and tans only slightly, after sun exposure

- Test site for solar-simulated ultraviolet radiation exposure (buttocks) devoid of sunburn, suntan, scars, active dermal lesions, and uneven skin tones

- Nevi allowed at physician discretion

- Excess hair must be clipped or shaved

- No prior nonmelanoma skin cancer, melanoma, or dysplastic nevi

PATIENT CHARACTERISTICS:

Age

- 18 to 45

Performance status

- Not specified

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

Other

- No prior malignancy

- No prior phototoxic, photoallergic, or other abnormal responses to sunlight

- No prior allergic reaction to sunscreen or lidocaine

- No underlying disease that is known to cause immunosuppression (e.g., HIV, cancer, or post-organ transplantation)

- No situation that would preclude study compliance

- Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- Not specified

Endocrine therapy

- Not specified

Radiotherapy

- Not specified

Surgery

- Not specified

Other

- More than 6 months since prior topical or systemic medication producing abnormal sunlight responses

- No concurrent medications with > 1% incidence of sun-related toxic effects

- No concurrent medications associated with abnormal light response

- No concurrent immunosuppressants

- No other concurrent ultraviolet radiation (e.g., sunlight or tanning bed) to the epidermal test site

Study Design

N/A


Intervention

Genetic:
microarray analysis

Procedure:
biopsy

evaluation of cancer risk factors


Locations

Country Name City State
United States Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT00550589 - Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus Phase 2
Completed NCT00653146 - The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia N/A
Terminated NCT00629577 - Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples Phase 1
Completed NCT00103246 - Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides Phase 1
Completed NCT00066430 - Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Phase 1
Completed NCT00522197 - ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia Phase 2
Completed NCT00003384 - Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer N/A
Terminated NCT02574442 - Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer
Completed NCT00719563 - American Ginseng in Treating Patients With Fatigue Caused by Cancer Phase 3
Terminated NCT00899951 - Studying Fentanyl in Patients With Cancer N/A
Terminated NCT00611650 - Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia Phase 2
Completed NCT00873288 - Activating Collaborative CIS Support Via Targeted Provider Mailing N/A
Completed NCT00462813 - Diindolylmethane in Treating Patients With Abnormal Cervical Cells Phase 3
Completed NCT00006348 - Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Phase 3
Completed NCT00666731 - Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition
Completed NCT00685568 - Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis Phase 1
Terminated NCT00942422 - Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Phase 2
Completed NCT00788164 - Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia Phase 1